Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection.
Bisphosphonates
Glycoproteins
Immune response
SARS Coronavirus
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
29 06 2020
29 06 2020
Historique:
received:
04
05
2020
accepted:
24
06
2020
entrez:
1
7
2020
pubmed:
1
7
2020
medline:
22
7
2020
Statut:
epublish
Résumé
Amino-bisphosphonates such as zoledronic acid (ZA) can possibly ameliorate or prevent severe COVID-19 disease by at least three distinct mechanisms: (1) as immunostimulants which could boost γδ T cell expansion, important in the acute response in the lung; (2) as DC modulators, limiting their ability to only partially activate T cells; and (3) as prenylation inhibitors of small GTPases in the endosomal pathway of the DC to prevent expulsion of lysosomes containing SARS-CoV-2 virions. Use of ZA or other amino-bisphosphonates as modulators of COVID-19 disease should be considered.
Identifiants
pubmed: 32600410
doi: 10.1186/s12967-020-02433-6
pii: 10.1186/s12967-020-02433-6
pmc: PMC7322393
doi:
Substances chimiques
Diphosphonates
0
Immunologic Factors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
261Références
Front Immunol. 2018 Jun 08;9:1246
pubmed: 29937767
Mayo Clin Proc. 2008 Sep;83(9):1032-45
pubmed: 18775204
Oncoimmunology. 2015 Apr 1;4(8):e1021538
pubmed: 26405575
Chin Med J (Engl). 2020 May 5;133(9):1051-1056
pubmed: 32149769
Stem Cell Reports. 2015 Jun 9;4(6):984-94
pubmed: 26004632
Virus Res. 2005 Jan;107(1):93-101
pubmed: 15567038
Small GTPases. 2011 May;2(3):117-130
pubmed: 21776413
Blood. 2008 Dec 15;112(13):5074-83
pubmed: 18768394
Transl Res. 2019 Jan;203:88-96
pubmed: 30194922
Antiviral Res. 2011 Apr;90(1):64-9
pubmed: 21356245
Nature. 2020 Jul;583(7816):459-468
pubmed: 32353859
Cold Spring Harb Perspect Biol. 2014 Oct 23;6(11):a022616
pubmed: 25341920
Immunopharmacol Immunotoxicol. 2009;31(3):499-508
pubmed: 19555208
Clin Exp Immunol. 2005 Jan;139(1):101-11
pubmed: 15606619
J Exp Med. 2011 Jul 4;208(7):1511-22
pubmed: 21708931
Eur J Pharm Sci. 2016 Jan 20;82:1-10
pubmed: 26542347
Immunity. 2018 Feb 20;48(2):350-363.e7
pubmed: 29426701
Blood. 2000 Jul 15;96(2):384-92
pubmed: 10887096
Front Cell Dev Biol. 2019 Jun 11;7:93
pubmed: 31263697
Nat Rev Genet. 2018 Dec;19(12):756-769
pubmed: 30305704
PLoS One. 2016 Oct 18;11(10):e0165004
pubmed: 27755597
Front Immunol. 2012 Mar 07;3:37
pubmed: 22566920
Blood. 2011 Sep 8;118(10):2743-51
pubmed: 21673342
Front Pharmacol. 2018 Jun 26;9:642
pubmed: 29997500
Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12540-5
pubmed: 16894145
J Infect Dis. 2006 May 1;193(9):1244-9
pubmed: 16586361
Cell Death Dis. 2014 Nov 13;5:e1517
pubmed: 25393473
Cancer Immunol Immunother. 2009 Jan;58(1):31-8
pubmed: 18458903
Clin Breast Cancer. 2009 May;9(2):77-85
pubmed: 19433387
Cancer Immunol Immunother. 2013 Apr;62(4):677-87
pubmed: 23151944
mSystems. 2020 May 5;5(3):
pubmed: 32371472
PLoS Pathog. 2009 Oct;5(10):e1000636
pubmed: 19851468
Transl Lung Cancer Res. 2014 Feb;3(1):23-33
pubmed: 25806278
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Nat Med. 2020 Jul;26(7):1070-1076
pubmed: 32514174
mBio. 2018 May 22;9(3):
pubmed: 29789363
J Bone Miner Res. 2000 Aug;15(8):1467-76
pubmed: 10934645
J Clin Oncol. 2007 Mar 1;25(7):829-36
pubmed: 17159193
Curr Opin Immunol. 2016 Oct;42:105-112
pubmed: 27491008
Cancer Res. 2007 Aug 1;67(15):7450-7
pubmed: 17671215
Lancet Oncol. 2014 Aug;15(9):997-1006
pubmed: 25035292
Lancet. 2015 Oct 3;386(10001):1353-1361
pubmed: 26211824
Clin Transl Immunology. 2019 Sep 23;8(9):e1079
pubmed: 31559018
J Biol Chem. 2001 May 11;276(19):15961-7
pubmed: 11278429
Cancer Res. 2014 Mar 1;74(5):1349-60
pubmed: 24448235
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
J Exp Med. 1996 Apr 1;183(4):1681-96
pubmed: 8666926
J Virol. 2005 Aug;79(15):9388-96
pubmed: 16014902